A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability, efficacy, pharmacokinetics,
and pharmacodynamics of CAN106 administered intravenously to subjects with PNH who have not
previously been treated with a complement inhibitor.